Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
#765 Everolimus Treatment in a Series of Patients with Advanced Neuroendocrine Tumors
Introduction: Everolimus is an oral mTOR inhibitor that exerts antineoplastic effects inhibiting cell proliferation, survival and angiogenesis. Its activity in advanced neuroendocrine tumors (NETs) has been demonstrated in controlled trials and everolimus was approved by the FDA for the treatment of progressive, advanced pNETs in May 2011.
Conference: 10th Annual ENETSConcerence (2013)
Presenting Author:
Authors: Plastino F, Iacovazzo D, Schinzari G, Barile R, Lugli F,
Keywords: everolimus, prrt,
Our website automatically sets cookies, which are technically necessary for the operation of the website. By clicking "OK", Google Analytics and the associated cookies are also activated for the purpose of website analysis and optimization. Detailed Information and the possibility to revoke your consent at any time, you can find in our privacy policy.
These cookies are so-called "session cookies." They are automatically deleted after your visit.
Protects you from Cross-Site-Request-Forgery attacks.
Saves the current PHP session.
For webinar purposes, ENETS uses VIMEO as an embedded iframe on MY ENETS. VIMEO implements its own tracking system, which is beyond the of ENETS responsibility. By watching ENETS videos on the ENETS website, you also agree to the conditions of VIMEO: https://vimeo.com/privacy
This website uses Google Analytics, a web analytics service. It is operated by Google Inc., 1600 Amphitheatre Parkway, Mountain View, CA 94043, USA. Google Analytics cookies are stored based on your consent Art. 6 (1) (a) DSGVO/GDPR, which we confirm via the consent banner.
For more information about how Google Analytics handles user data, see Google's privacy policy: https://support.google.com/analytics/answer/6004245?hl=en.
